The U Tokyo group has identified an ATL novel tumor Antigen (GARP) Anti-GARP mAbs induced specific ADCC against primary ATL cells. This may be a badly needed new therapeutic target. #HTLV2024

Bexarotene is effective for skin disease in ATL. ORR 71% in 300 mg/m2/d group. efect can be seen for skin lesions in idolent ATL but also residual ore relapsed skin lesions with aggressive ATL. safety profile as expected from CTCL studies. #HTLV2024

Remarkable outcomes from alloSCT in first remission from the French experience. Significantly better than other data presented. Reason for difference not clear but perhaps donor choice and post transplant cytoxan may play a role. #HTLV2024

CD30 expression intensity in ATL doesn't correlate between IHC/histology and flow cytometry (although similar numbers of 'positivity')

Studying HIV/HTLV coinfected patients to ascertain effects of antiretroviral therapy on HTLV replication. integrase inhibs assoc w low proviral loads. #HTLV2024

Several antiretrovirals can block HTLV-1 cell culture transmission at even lower EC50s than HIV. The integrase inhibitors and tenofovir are by far the most promising. #HTLV2024

Make Duffy antigen testing easy to order. Make interpretation simple. Identify Duffy-null Associated Neutrophil Counts (#DANC) to facilitate appropriate medication dosing, avoid unnecessary work up and minimize systemic bias. Lauren Merz Boston Medical Center Jean francis

Alright everyone. The RVUs are back at zero. Let’s do this!

Shout out to my patient who just referred to getting daratumumab without premeds as ‘Raw-dogging it’

Observation from a program director currently reading through hundreds of applications: you guys are killing me with the AI-generated personal statements.

In the Navajo there is no word for cancer. It is typically called "Lood doo na'ziihii" which literally means "The wound that does not heal." Much respect to IndianHealthService for figuring out how to deliver effective cancer care in challenging circumstances centerforhealthjournalism.org/our-work/repor…

These are my own but I suspect most program directors would feel the same.

IgM AL is a confusing disease article by Morie Gertz et al ncbi.nlm.nih.gov/pmc/articles/P… -it's hard but important to identify underlying clone (plasma cell vs LPL). -~2/3 are LPL -there are clonal plasma cells even in LPL. -t(11;14) = PC; MYD88 = LPL -rituximab based tx for LPL

Green flags in fellowship applications. Competitive programs have space to interview <10% of applicants so anything you want us to know needs to be conveyed in the application itself-- you can't wait for the interview to make a case for 'fit'.

Ever wondered what STRUCTURAL RACISM is? Important work from my friend Stephen Hibbs in JAMA Network Open Those with Duffy null associated low neutrophil counts are excluded from cancer trials + optimal therapy A🧵 @krutbvora, Chris Lathan, J Mark Sloan, Lauren Merz, Dr Vanessa Apea